



(12) **EUROPEAN PATENT APPLICATION**  
published in accordance with Art. 158(3) EPC

(43) Date of publication:  
05.09.2001 Bulletin 2001/36

(21) Application number: 99972223.4

(22) Date of filing: 12.11.1999

(51) Int Cl.7: **C07K 14/47, C12N 15/12,**  
**C07K 16/18, C12P 21/08**  
**// (C12N1/21, C12P21:02),**  
**C12N15:12, C12R1:91,**  
**C12P21:02, C12R1:19**

(86) International application number:  
**PCT/JP99/06309**

(87) International publication number:  
**WO 00/29436 (25.05.2000 Gazette 2000/21)**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU**  
**MC NL PT SE**

(30) Priority: 12.11.1998 JP 32267498

(71) Applicant: **Japan Science and Technology**  
**Corporation**  
**Kawaguchi-shi, Saitama 332-0012 (JP)**

(72) Inventors:  
• **SUGAMURA, Kazuo, Univ. of Tohoku,**  
**Medical Dept.**  
**Sendai-shi, Miyagi 980-0872 (JP)**  
• **TANAKA, Nobuyuki, Univ. of Tohoku,**  
**Medical Dept.**  
**Sendai-shi, Miyagi 980-0872 (JP)**

(74) Representative: **Webber, Philip Michael**  
**Frank B. Dehn & Co.,**  
**179 Queen Victoria Street**  
**London EC4V 4EL (GB)**

(54) **PROTEIN AMSH AND CDNA THEREOF**

(57) This application provides a human protein AMSH having the amino acid sequence of SE ID No. 1 which is a novel signal transduction molecule interacting

with the SH3 domain of cytokine based signal transduction molecule STAM; a gene encoding the above AMSH; a cDNA having the nucleotide sequence of SEQ ID No. 2; and antibody against AMSH.

**Description****Technical Field**

5 [0001] The present invention relates to human protein hAMSH and mouse protein mAMSH, and cDNAs encoding these proteins. More particularly, the present invention relates to novel human and mouse signal transduction molecules, AMSH, human and mouse genes encoding these proteins, cDNAs thereof, and antibodies against these proteins.

**Background Art**

10 [0002] A variety of cells having different functions should collaborate with each other for expression of higher biological functions such as hematopoietic, immunological and nervous systems. Communication among the cells is essential for their collaborations. Cytokines are known to be the proteins responsible for intercellular communication, and include interleukin (IL)-1 to 18, colony stimulation factors (CSFs), interferons (IFNs) and several chemokines.

15 [0003] Signals are generated by binding of the cytokines to specific receptors on the cell membrane, and survival, proliferation, differentiation and functional expression of the cells are controlled by signal transduction. Accordingly, dysfunction of cytokine-receptor signal transduction pathways result in collapse of the immunological and hematopoietic systems to cause severe infectious diseases, cancers and autoimmune diseases.

20 [0004] For the reasons described above, it is quite important to elucidate the intracellular signal transduction pathways mediated by the cytokine/cytokine receptor system. This is important, in order to appreciate the basic phenomena such as proliferation and differentiation of the cells, pathogenesis, diagnosis and therapeutic intervention of various diseases at the molecular levels.

25 [0005] The inventors of the present invention have isolated the genes of "common  $\gamma$ -chain" commonly included in a plurality of the cytokine receptors, and have made a great contribution in elucidating the structure and function of the cytokine receptors. Of particular elucidation is that the  $\gamma$ -chain is an essential subunit for functional expression of IL-2, IL-4, IL-7 and IL-9, and abnormality in the  $\gamma$ -chain causes impairment of early development of T-cells via dysfunction of IL-7 (Science, 262:1874-1877, 1993; Int. Immunol., 6:1451-1454, 1994; Science, 263:1453-1454, 1994; Eur. J. Immunol., 25:3001-3005, 1995).

30 [0006] Recently, the inventors of the present invention have identified "STAMs" as novel signal molecules concerning signal transduction in the proliferating cells by the cytokines, and found that these STAMs are present downstream of the IL-2/GM-CSF receptor and directly associate with JAK3/2. The inventors also found that STAMs play an important role in expression of c-myc and signal transduction for DNA synthesis (Immunity, 6:449-457, 1997).

35 [0007] While several important mechanisms of the intracellular signal transduction pathway by binding of the cytokines to the receptors have been made clear, additional novel molecules should be identified for elucidating the overall structure and function of the intracellular signal transduction pathway, because plural molecules are thought to be continuously and synergetically involved in the signal transduction pathway and to manifest final functional expression by constructing a so-called cascade.

40 [0008] The present invention was performed by taking the above situations into consideration, and the object of this invention is to provide a novel signal transduction molecules interacting with SH3 domain of a signal molecule STAM that has been found by the present inventors, and exerting essential functions on signal transduction to the downstream from STAM.

[0009] Another object of the present invention is to provide gene encoding this novel molecule, cDNA thereof, and antibody against the novel molecule.

**Disclosure of Invention**

[0010] The present invention for solving the foregoing problems provides a human protein hAMSH having the amino acid sequence of SEQ ID No. 1

50 [0011] The present invention also provides a human gene encoding the human protein hAMSH, hAMSH cDNA having the nucleotide sequence of SEQ ID No. 2, and a DNA fragment comprising a partial sequence of SEQ ID No. 2.

[0012] The present invention further provides a recombinant vector containing the cDNA or the partial fragment thereof, and an antibody against the human protein hAMSH.

55 [0013] The present invention additionally provides a mouse protein mAMSH having the amino acid sequence of SEQ ID No. 3, a mouse gene encoding the mouse protein mAMSH, mAMSH cDNA having the nucleotide sequence of SEQ ID No. 4, a DNA fragment comprising a partial sequence of SEQ ID No. 4, a recombinant vector containing the cDNA or the DNA fragment thereof, and an antibody against the mouse protein mAMSH.

**Best Mode for Carrying Out the Invention**

[0014] The procedure for obtaining a human protein hAMSH and cDNA thereof, as well as the procedure for identifying the function of the protein will be described hereinafter.

5 [0015] The human protein hAMSH cDNA according to the present invention is a human gene's cDNA isolated by screening a human cDNA library by Far-Western method using a chimera gene of SH3 domain of STAM gene and glutathione-S-transferase (GST). This cDNA has a nucleotide sequence comprising 1910 base pairs shown in SEQ ID No. 2, and encodes the protein hAMSH having the amino acid sequence of SEQ ID No. 1.

10 [0016] While estimated a nucleus transfer signal and a JAB1-like structure are observed in the molecule of the protein hAMSH, this protein is confirmed to be a novel molecule since corresponding molecules are not found in the protein data base.

[0017] The facts that this protein hAMSH is a novel molecule involved in signal transduction for cell proliferation by association with STAM, downstream of the cytokine receptor, is confirmed as follows:

- 15 (1) AMSH-dc2 in which half of the C-terminal region of hAMSH has been deleted, suppresses signal transduction for DNA synthesis after stimulating with IL-2 and GM-CSF; and  
 (2) The AMSH-dc2 mutant suppresses c-myc inducing signal transduction after stimulating with IL-2 and GM-CSF.

20 [0018] The cDNA of the mouse protein mAMSH according to the present invention is a mouse gene's cDNA isolated by screening a mouse cDNA library using the hAMSH cDNA as a probe. This cDNA has the nucleotide sequence comprising 1384 base pairs shown in SEQ ID No. 4, and encodes the protein mAMSH having the amino acid sequence of SEQ ID No. 3.

25 [0019] The proteins hAMSH and mAMSH according to the present invention may be obtained by conventional methods such as isolating from human or mouse organs or from cell lines, preparing the peptides by a chemical synthesis based on the amino acid sequence provided by the present invention, or by a recombinant DNA techniques using the cDNA fragments provided by the present invention. For example, in order to obtain the protein hAMSH by the recombinant DNA technique, RNA is prepared by in vitro transcription from the vectors comprising cDNA fragment having the nucleotide sequence of SEQ ID No. 2, and the protein may be expressed through in vitro translation using the RNA as a template. The protein encoded by the cDNA may be also expressed in large scale in *E. coli*, *Bacillus subtilis*, yeast, animal cells and plant cells by recombining an expression vector with the translation region of cDNA by known methods in the art.

30 [0020] When the protein according to the present invention is produced by expression of DNA by in vitro translation, the cDNA or its translation region is recombined into a vector having a RNA polymerase promoter, and the recombinant cDNA is added in an in vitro translation system such as a rabbit dialyzate or wheat germ extract containing a RNA polymerase for the promoter. Examples of the RNA polymerase promoter include T6, T3 and SP6. Examples of the vector containing these RNA polymerase promoter include pKA1, pCDM8, pT3/7 18, pT7/3 19 and pBlueprint II.

35 [0021] For large scale production of the protein encoded in cDNA in microorganisms such as *E. coli*, an expression vector is constructed by inserting the cDNA according to the present invention or its translation region into an expression vector comprising an origin suitable for microorganisms, a promoter, a ribosome binding site, cDNA cloning sites and terminator, followed by cultivation of the transformant cell obtained after translocation of the host cell with the expression vector. A protein containing an arbitrary region can be obtained by allowing the expression vector to express by adding an initiation codon and a stop codon before and after the arbitrary translation region. Otherwise, a desired protein portion can be selectively obtained by allowing the protein to express as a fusion protein with other protein, followed by cleaving this fusion protein with an appropriate protease. Examples of the expression vector for use in *E. coli* include pUC, pBluescript II, pET expression system and pGEX expression system.

45 [0022] For producing the protein according to the present invention in eukaryotic cell such as animal cells, the cDNA or the translation region thereof is inserted into an expression vector for the eukaryotic cell comprising a promoter, splicing region and poly (A) addition site to introduce the recombinant vector into the eukaryotic cell. Examples of the expression vector include pKA1, pCDM8, pSVK3, pMSG, pSVL, pBK-CMV, pBK-RSV, EBV vector, pRS and pYES2. While cultured cells of a mammal such as monkey kidney cells COS7 and Chinese hamster ovary cells CHO, budding yeast, dividing yeast, silkworm cells and African clawed frog egg cells are usually used as the eukaryotic cells, any eukaryotic cells may be used so long as they are able to express MIST. The expression vector can be introduced into the eukaryotic cell by a conventional method such as an electroporation method, a calcium phosphate method, a liposome method and a DEAE dextran method.

50 [0023] Separation procedures known in the art may be combined for isolating and purifying the desired protein from the culture after expressing the protein in microorganisms or eukaryotic cells. The separation and purifying methods include, for example, treatment with a denaturation reagent such as urea or with a surface active agent, ultrasonic treatment, enzymatic digestion, salting-out and solvent precipitation method, dialysis, centrifugation, ultrafiltration, gel

filtration, SDS-PAGE, isoelectric point electrophoresis, ion exchange chromatography, hydrophobic chromatography, affinity chromatography and reversed phase chromatography.

[0024] Peptide fragments (five amino acid residues or more) containing any partial amino acid sequence of the amino acid sequence of SEQ ID Nos 1 and 3 are included in the proteins hAMSH and mAMSH according to the present invention. These peptide fragments may be used for producing antibodies. Fusion proteins with other proteins are also included in the protein according to the present invention.

[0025] The gene of the present invention is a human gene encoding the protein described above, and can be isolated, for example, from the existing genome library using the cDNA of the present invention or a partial sequence thereof as a probe.

[0026] The cDNA of the present invention may be obtained by screening a cDNA library derived from a human cell or mouse cell through colony or plaque hybridization known in the art by using the oligonucleotide probe synthesized, based on the nucleotide sequence of SEQ ID Nos. 2 and 4. Alternatively, the cDNA of the present invention can be prepared from the mRNA isolated from a human cell or mouse cell by the RT-PCR method using synthesized oligonucleotides that can hybridize to both ends of the cDNA fragment as primers.

[0027] Polymorphism due to individual differences is often observed in the animal gene. Accordingly, cDNAs containing an addition or deletion of one or plural nucleotides, and/or substitution with other nucleotides in SEQ ID Nos. 2 and 4 are also included within the scope of the present invention.

[0028] Likewise, the proteins containing an addition or deletion of one or plural amino acids, and/or substitution with other amino acids caused by the alteration of cDNAs may be also included within the scope of the present invention, provided that the protein comprises protein activity of the protein having the amino acid sequence of SEQ ID No. 1 or 3.

[0029] The DNA fragments (10 bp or more) comprising any partial nucleotide sequence of SEQ ID No. 2 or 4 are also included in the DNA fragment of the present invention. DNA fragments comprising sense strand and antisense strand may be categorized into the DNA fragment of the present invention. The DNA fragments can be used as a probe for gene diagnosis.

[0030] Antibodies against the proteins of the present invention may be obtained as polyclonal antibodies or monoclonal antibodies by conventional methods using the proteins themselves or partial peptides thereof as antigens.

#### Example

[0031] A part of the hAMSH cDNA (the 383-550th in SEQ ID No. 2: corresponds to the amino acids 125-180th in SEQ ID No. 1) was amplified by PCR and was inserted into the GST fusion protein expression vector. This vector was introduced into E coli for transformation, and this transformant was stimulated with IPTG to induce expression of the GST fusion protein. The induced fusion protein was purified by affinity chromatography using a glutathione column, thereby obtaining the GST fusion protein. An antiserum was obtained by immunizing a rabbit with this GST fusion protein as an antigen.

#### Industrial Applicability

[0032] As hitherto described in detail, the present invention provides novel signal transduction molecules related to the cytokine based signal transduction pathway, and gene engineering materials. These molecules and gene engineering materials are useful for developing diagnostic and therapeutic methods as well as pharmaceuticals for human diseases due to dysfunction of the cytokine based signal transduction pathway such as severe infectious diseases, cancers and autoimmune diseases.

## SEQUENCE LISTING

5 <110> Japan Science and Technology Corporation  
 <120> Protein AMSH and cDNA thereof  
 <130> 99-F-054PCT/YS  
 10 <140> PCT/JP99/06309  
 <141> 1999-11-12  
 15 <150> JP No. 10-322674  
 <151> 1998-11-12  
 <160> 4  
 20 <170> PatentIn Ver. 2.0  
 <210> 1  
 <211> 424  
 25 <212> PRT  
 <213> Homo sapiens  
 30 <400> 1  
 Met Ser Asp His Gly Asp Val Ser Leu Pro Pro Glu Asp Arg Val Arg  
 1 5 10 15  
 35 Ala Leu Ser Gln Leu Gly Ser Ala Val Glu Val Asn Glu Asp Ile Pro  
 20 25 30  
 40 Pro Arg Arg Tyr Phe Arg Ser Gly Val Glu Ile Ile Arg Met Ala Ser  
 35 40 45  
 Ile Tyr Ser Glu Glu Gly Asn Ile Glu His Ala Phe Ile Leu Tyr Asn  
 45 50 55 60  
 Lys Tyr Ile Thr Leu Phe Ile Glu Lys Leu Pro Lys His Arg Asp Tyr  
 65 70 75 80  
 50 Lys Ser Ala Val Ile Pro Glu Lys Lys Asp Thr Val Lys Lys Leu Lys  
 85 90 95  
 55 Glu Ile Ala Phe Pro Lys Ala Glu Glu Leu Lys Ala Glu Leu Leu Lys

	100	105	110	
5	Arg Tyr Thr Lys Glu Tyr Thr Glu Tyr Asn Glu Glu Lys Lys Lys Glu			
	115	120	125	
	Ala Glu Glu Leu Ala Arg Asn Met Ala Ile Gln Gln Glu Leu Glu Lys			
10	130	135	140	
	Glu Lys Gln Arg Val Ala Gln Gln Lys Gln Gln Gln Leu Glu Gln Glu			
15	145	150	155	160
	Gln Phe His Ala Phe Glu Glu Met Ile Arg Asn Gln Glu Leu Glu Lys			
	165	170	175	
20	Glu Arg Leu Lys Ile Val Gln Glu Phe Gly Lys Val Asp Pro Gly Leu			
	180	185	190	
	Gly Gly Pro Leu Val Pro Asp Leu Glu Lys Pro Ser Leu Asp Val Phe			
25	195	200	205	
	Pro Thr Leu Thr Val Ser Ser Ile Gln Pro Ser Asp Cys His Thr Thr			
30	210	215	220	
	Val Arg Pro Ala Lys Pro Pro Val Val Asp Arg Ser Leu Lys Pro Gly			
	225	230	235	240
35	Ala Leu Ser Asn Ser Glu Ser Ile Pro Thr Ile Asp Gly Leu Arg His			
	245	250	255	
40	Val Val Val Pro Gly Arg Leu Cys Pro Gln Phe Leu Gln Leu Ala Ser			
	260	265	270	
	Ala Asn Thr Ala Arg Gly Val Glu Thr Cys Gly Ile Leu Cys Gly Lys			
45	275	280	285	
	Leu Met Arg Asn Glu Phe Thr Ile Thr His Val Leu Ile Pro Lys Gln			
	290	295	300	
50	Ser Ala Gly Ser Asp Tyr Cys Asn Thr Glu Asn Glu Glu Glu Leu Phe			
	305	310	315	320
55	Leu Ile Gln Asp Gln Gln Gly Leu Ile Thr Leu Gly Trp Ile His Thr			

5                   325                   330                   335  
 His Pro Thr Gln Thr Ala Phe Leu Ser Ser Val Asp Leu His Thr His  
                   340                   345                   350  
 10 Cys Ser Tyr Gln Met Met Leu Pro Glu Ser Val Ala Ile Val Cys Ser  
                   355                   360                   365  
 Pro Lys Phe Gln Glu Thr Gly Phe Phe Lys Leu Thr Asp His Gly Leu  
 15                   370                   375                   380  
 Glu Glu Ile Ser Ser Cys Arg Gln Lys Gly Phe His Pro His Ser Lys  
 385                   390                   395                   400  
 20 Asp Pro Pro Leu Phe Cys Ser Cys Ser His Val Thr Val Val Asp Arg  
                   405                   410                   415  
 25 Ala Val Thr Ile Thr Asp Leu Arg

420

&lt;210&gt; 2

&lt;211&gt; 1910

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;221&gt; CDS

&lt;222&gt; 11..1282

&lt;400&gt; 2

40   cttggctctg atgtctgacc atggagatgt gagcctcccg cccgaagacc gggtagggc 60  
     tctctcccag ctgggtagtg cggtagaggt gaatgaagac attccacccc gtcggtactt 120  
 45   ccgctctgga gttgagatta tccgaatggc atccatttac tctgaggaag gcaacattga 180  
     acatgccttc atcctctata acaagtatat cacgctcttt attgagaaac taccaaaaca 240  
     tcgagattac aaatctgctg tcattcctga aaagaaagac acagtaaaga aattaaagga 300  
 50   gattgcattt cccaaagcag aagagctgaa ggcagagctg ttaaaacgat ataccaaaga 360  
     atatacagaa tataatgaag aaaagaagaa ggaagcagag gaattggccc ggaacatggc 420  
 55   catccagcaa gagctggaaa aggaaaaaca gaggtagca caacagaagc agcagcaatt 480

ggaacaggaa cagttccatg ccttcgagga gatgatccgg aaccaggagc tagaaaaaga 540  
 5 ggcactgaaa attgtacagg agtttgggaa ggtagaccct ggcttaggtg gcccgctagt 600  
 gcctgacttg gagaagccct ccttagatgt gttccccacc ttaacagtct catccataca 660  
 10 gccttcagac tgtcacacaa ctgtaaggcc agctaagcca cctgtggtgg acaggtcctt 720  
 gaaacctgga gcactgagca actcagaagc tattcccaaca atcgatggat tgcgccaatgt 780  
 ggtggtgcct gggcggctgt gccacagtt tctccagtta gccagtcca acactgcccg 840  
 15 gggagtggag acatgtggaa ttctctgtgg aaaactgatg aggaatgaat ttaccattac 900  
 ccatgttctc atccccaagc aaagtgcctg gtctgattac tgcaacacag agaacgaaga 960  
 agaacttttc ctcatacagg atcagcaggc cctcatcaca ctgggctgga ttcataactca 1020  
 20 cccacacag accgcgtttc tctccagtgt cgacctacac actcactgct cttaccagat 1080  
 gatgttgcca gagtcagtag ccattgtttg ctccccaag ttccaggaaa ctggattcctt 1140  
 25 taaactaact gaccatggac tagaggagat ttcttctgt cgccagaaag gatttcatcc 1200  
 acacagcaag gatccacctc tgttctgtag ctgcagccac gtgactgttg tggacagagc 1260  
 agtgaccatc acagaccttc gatgagcgtt tgagtccaac acctccaag aacaacaaaa 1320  
 30 ccatatcagt gtactgtagc cccttaattt aagctttcta gaaagctttg gaagtttttg 1380  
 tagatagtag aaaggggggc atcacctgag aaagagctga tttgtattt caggtttgaa 1440  
 aagaaataac tgaacatatt ttttaggcaa gtcagaaaga gaacatggc acccaaaagc 1500  
 35 aactgtaact cagaaattaa gtactcaga aattaagtag ctcaaaatt aagaaagaat 1560  
 ggtataatga acccccatat acccttcctt ctggattcac caattgttaa catttttttc 1620  
 40 ctctcagcta tccttctaatt ttctctctaa ttcaatttg tttatattta cctctgggct 1680  
 caataagggc atctgtgcag aaatttgaa gccatttaga aaatctttg gattttcctg 1740  
 tggtttatgg caatatgaat ggagcttatt actgggggtga gggacagctt actccatttg 1800  
 45 accagattgt ttggctaaca catcccgaag aatgatttg tcaggaatta ttgttattta 1860  
 ataaatatat caggatatat ttctctaca ataaagtaac aattaactta 1910  
 50 <210> 3  
 <211> 424  
 <212> PRT  
 55 <213> mouse



&lt;400&gt; 3

5	Met Ser Asp His Gly Asp Val Ser Leu Pro Pro Gln Asp Arg Val Arg
	1 5 10 15
10	Ile Leu Ser Gln Leu Gly Ser Ala Val Glu Leu Asn Glu Asp Ile Pro
	20 25 30
15	Pro Arg Arg Tyr Tyr Arg Ser Gly Val Glu Ile Ile Arg Met Ala Ser
	35 40 45
	Val Tyr Ser Glu Glu Gly Asn Ile Glu His Ala Phe Ile Leu Tyr Asn
	50 55 60
20	Lys Tyr Ile Thr Leu Phe Ile Glu Lys Leu Pro Lys His Arg Asp Tyr
	65 70 75 80
25	Lys Ser Ala Ile Ile Pro Glu Lys Lys Asp Ala Val Lys Lys Leu Lys
	85 90 95
	Ser Val Ala Phe Pro Lys Ala Glu Glu Leu Lys Thr Glu Leu Leu Arg
30	100 105 110
	Arg Tyr Thr Lys Glu Tyr Glu Gln Tyr Lys Glu Arg Lys Lys Lys Glu
	115 120 125
35	Glu Glu Glu Leu Ala Arg Asn Ile Ala Ile Gln Gln Glu Leu Glu Lys
	130 135 140
40	Glu Lys Gln Arg Val Ala Gln Gln Lys Gln Lys Gln Leu Glu Gln Glu
	145 150 155 160
	Gln Phe His Ala Phe Glu Glu Met Ile Gln Arg Gln Glu Leu Glu Lys
45	165 170 175
	Glu Arg Leu Lys Ile Val Gln Glu Phe Gly Lys Val Asp Pro Gly Pro
	180 185 190
50	Cys Gly Pro Leu Leu Pro Asp Leu Glu Lys Pro Cys Val Asp Val Ala
	195 200 205
55	Pro Ser Ser Pro Phe Ser Pro Thr Gln Thr Pro Asp Cys Asn Thr Gly

	210	215	220	
5	Met Arg Pro Ala Lys Pro Pro Val Val Asp Arg Ser Leu Lys Pro Gly			
	225	230	235	240
	Ala Leu Ser Val Ile Glu Asn Val Pro Thr Ile Glu Gly Leu Arg His			
10		245	250	255
	Ile Val Val Pro Arg Asn Leu Cys Ser Glu Phe Leu Gln Leu Ala Ser			
15		260	265	270
	Ala Asn Thr Ala Lys Gly Ile Glu Thr Cys Gly Val Leu Cys Gly Lys			
	275	280	285	
20	Leu Met Arg Asn Glu Phe Thr Ile Thr His Val Leu Ile Pro Arg Gln			
	290	295	300	
25	Asn Gly Gly Pro Asp Tyr Cys His Thr Glu Asn Glu Glu Glu Ile Phe			
	305	310	315	320
	Phe Met Gln Asp Asp Leu Gly Leu Leu Thr Leu Gly Trp Ile His Thr			
30		325	330	335
	His Pro Thr Gln Thr Ala Phe Leu Ser Ser Val Asp Leu His Thr His			
35		340	345	350
	Cys Ser Tyr Gln Met Met Leu Pro Glu Ser Ile Ala Ile Val Cys Ser			
	355	360	365	
40	Pro Lys Phe Gln Glu Thr Gly Phe Phe Lys Leu Thr Asp Tyr Gly Leu			
	370	375	380	
45	Gln Glu Ile Ser Thr Cys Arg Gln Lys Gly Phe His Pro His Gly Arg			
	385	390	395	400
	Asp Pro Pro Leu Phe Cys Asp Cys Ser His Val Thr Val Lys Asp Arg			
50		405	410	415
	Ile Val Thr Ile Thr Asp Leu Arg			
	420			
55	<210> 4			

&lt;211&gt; 1384

&lt;212&gt; DNA

&lt;213&gt; homosapiens

&lt;221&gt; CDS

&lt;222&gt; 56..1327

&lt;400&gt; 4

5                   gtgacgtttc cggaagctct gactgtcatt cttcacgaaa gaacttatit gtccaatgtc 60  
                   tgaccatggg gatgtgagcc tcccacccca agaccgggtg aggattctgt cccaacttgg 120  
                   gagtgagatt gagttaaatg aagacattcc acccgcgcgc tactaccgct ccggtgttga 180  
 10                   gatcatccgc atggcgctccg ttctactcga agaaggcaac attgaacatg cttttatcct 240  
                   ctacaacaag tacatcacgc tgtttattga aaaacttccg aaacaccgag actacaaatc 300  
                   agctatcatt cctgagaaga aagatgctgt caagaaatta aagagcgtcg ctttccttaa 360  
 20                   agcgggaagag ctgaagacag agctcttgag aagatacacc aaagaatatg agcagtataa 420  
                   agagcgaaag aaaaaggaag aagaggaact tgcccgaat atcgccatcc agcaagagtt 480  
                   ggaaaaagaa aaacagaggg ttgctcagca gaagcagaag cagctagagc aggagcaatt 540  
 30                   ccatgccitt gaggagatga tccagaggca ggagctggaa aaagaacggc tgaaaattgt 600  
                   tcaagagttc gggaaggtag accctggccc ctgcgggcct ctgctccctg atctggaaaa 660  
 35                   gccttgtgtg gatgtggccc ccagctcacc gttctcggcc acgcagactc cagactgtaa 720  
                   cacaggcatg aggccagcta agccacctgt ggtggacagg tccctgaaac ctggagcgtt 780  
                   aagcgtcata gaaaatgttc ccaccattga aggcctgcgc cacatcgttg tgccccgtaa 840  
 40                   tctgtgtcta gaatttctcc agcttgccag tgccaatacc gccaaaggca ttgaaacctg 900  
                   tggagtcctc tgtggaaaac tgatgagaaa tgaattcaca atcacacatg ttctcatccc 960  
 45                   cagacaaaat ggtgggcctg attattgcca cacggagaat gaagaagaaa ttttctttat 1020  
                   gcaggatgac cttggactcc tcactcttgg ctggatccat actcatccaa cccaaacggc 1080  
                   ctttctgtcc agtgtggatc tccacactca ctgctcctac caaatgatgt taccagagtc 1140  
 50                   catcgcaatc gtctgttccc caaagttcca ggaaactgga ttctttaagc taactgacta 1200  
                   tggtcttcaa gagatttcaa cctgccggca gaaaggcttt caccacctg gcagagaccc 1260  
 55                   accgctgttc tgtgactgca gccatgtcac tgtcaaggac agaattgtga cgatcacaga 1320

ccttcgataa atctcaaac atgaaccagg gagatggatc actgggtaac agcacttgtc 1380  
 acca 1384

5

# Claims

10

1. A human protein hAMSH having the amino acid sequence of SEQ ID No. 1.

2. A human gene encoding the human protein hAMSH of claim 1.

15

3. cDNA of the human gene of claim 2, which is hAMSH cDNA having the nucleotide sequence of SEQ ID no. 2.

4. A DNA fragment comprising a partial sequence in the nucleotide sequence of SEQ ID No. 2.

20

5. A recombinant vector containing the hAMSH cDNA of claim 4 or the DNA fragment of claim 4.

6. An antibody against the human protein hAMSH of claim 1.

7. A mouse protein mAMSH having the amino acid sequence of SEQ ID No. 3.

25

8. A mouse gene encoding the mouse protein mAMSH of claim 7.

9. cDNA of the mouse gene of claim 7, which is mAMSH cDNA having the nucleotide sequence of SEQ ID no. 4.

30

10. A DNA fragment comprising a partial sequence in the nucleotide sequence of SEQ ID No. 4.

11. A recombinant vector containing the mAMSH cDNA of claim 9 or the DNA fragment of claim 10.

12. An antibody against the mouse protein mAMSH of claim 7.

35

40

45

50

55

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP99/06309

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> Int.Cl <sup>7</sup> C07K 14/47, C12N 15/12, C07K 16/18, C12P 21/08 // C12N 1/21, C12P 21/02, (C12N 15/12, C12R 1:91), (C12P 21/02, C12R 1:19) According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) Int.Cl <sup>7</sup> C12N 15/00-90, C07K 14/00-16/46, C12P 21/00-08, C12N 1/00-38 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) MEDLINE (STN), Genbank/EMBL/DDBJ/GeneSeq, WPI (DIALOG), BIOSIS (DIALOG)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
PX PY	Kazuo Sugamura et al., "Possible involvement of a novel STAM-associated molecule "AMSH" in intracellular signal transduction mediated by cytokines", J.Biol.Chem. (July 1999), Vol.274, No.27, p.19129-19135	1- 6 7-12
X	Wei Yu et al., "Large-scale concatenation cDNA sequencing", Genome Research (1997), Vol.7, No.4, p.353-358	4,5,10,11
X	Meredith A.Wentland et al., "A Double Adaptor" method for improved shotgun library construction", Analytical Biochemistry (1996), Vol.236, No.1, p.107-113	4,5,10,11
A	Sugamura K. et al., "STAM, signal transducing adaptor molecule, is associated with Janus kinases and involved in signaling for cell growth and c-myc induction", Immunity (1997), Vol.6, No.4, p.449-457	1-12
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
Date of the actual completion of the international search 22 February, 2000 (22.02.00)		Date of mailing of the international search report 14 March, 2000 (14.03.00)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)